Goldwasser F - Search Results

1

Vazeille C, Jouinot A, Durand JP, Cynober L, Goldwasser F. Vazeille C, et al. Among authors: goldwasser f. Am J Clin Nutr. 2017 Sep;106(3):958-959. doi: 10.3945/ajcn.117.162107. Am J Clin Nutr. 2017. PMID: 28864589 Free article. No abstract available.

2

Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine.

Durand JP, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Anticancer Drugs. 2002 Aug;13(7):777-80. doi: 10.1097/00001813-200208000-00013. Anticancer Drugs. 2002. PMID: 12187335

3

Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.

Durand JP, Brezault C, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Anticancer Drugs. 2003 Jul;14(6):423-5. doi: 10.1097/00001813-200307000-00006. Anticancer Drugs. 2003. PMID: 12853883

4

[New challenges in medical oncology. From medical oncology to oncological medicine].

Durand JP, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Ann Med Interne (Paris). 2003 May;154(3):131-2. Ann Med Interne (Paris). 2003. PMID: 12910038 French. No abstract available.

5

Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.

Durand JP, Alexandre J, Guillevin L, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Anticancer Drugs. 2005 Jun;16(5):587-91. doi: 10.1097/00001813-200506000-00015. Anticancer Drugs. 2005. PMID: 15846125

6

Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.

Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand JP, Goldwasser F. Mir O, et al. Among authors: goldwasser f. Anticancer Drugs. 2009 Feb;20(2):105-8. doi: 10.1097/CAD.0b013e32831cdb51. Anticancer Drugs. 2009. PMID: 19209026 Clinical Trial.

7

Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.

Mir O, Ropert S, Babinet A, Alexandre J, Larousserie F, Durand JP, Enkaoua E, Anract P, Goldwasser F. Mir O, et al. Among authors: goldwasser f. Cancer Chemother Pharmacol. 2010 Nov;66(6):1059-63. doi: 10.1007/s00280-010-1259-3. Epub 2010 Feb 13. Cancer Chemother Pharmacol. 2010. PMID: 20155268 Clinical Trial.

8

Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.

Coriat R, Mir O, Cessot A, Brezault C, Ropert S, Durand JP, Cacheux W, Chaussade S, Goldwasser F. Coriat R, et al. Among authors: goldwasser f. Invest New Drugs. 2012 Feb;30(1):376-81. doi: 10.1007/s10637-010-9525-0. Epub 2010 Aug 27. Invest New Drugs. 2012. PMID: 20798975

9

Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status.

Cessot A, Hebuterne X, Coriat R, Durand JP, Mir O, Mateus C, Cacheux W, Lemarie E, Michallet M, de Montreuil CB, Goldwasser F; French Nutrition Oncology Study Group. Cessot A, et al. Among authors: goldwasser f. Support Care Cancer. 2011 Jul;19(7):869-70. doi: 10.1007/s00520-011-1122-z. Epub 2011 Mar 10. Support Care Cancer. 2011. PMID: 21387161 No abstract available.

10

Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients.

Durand JP, Mir O, Coriat R, Cessot A, Pourchet S, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Support Care Cancer. 2012 Apr;20(4):857-64. doi: 10.1007/s00520-011-1163-3. Epub 2011 Apr 16. Support Care Cancer. 2012. PMID: 21499844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

336 results

Search Page